Lenalidomid Fresenius Kabi (Lenalidomide)

Lenalidomide is employed in hematologic malignancies that involve abnormal plasma or lymphoid cells.

• Multiple Myeloma: improves progression‑free survival and overall response rates in adult patients.
• Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and can induce cytogenetic remission.
• Mantle Cell Lymphoma: provides disease control in relapsed or refractory cases.

• Lenalidomide binds to the cereblon component of the CRL4 E3 ubiquitin ligase complex, prompting the ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos. This leads to modulation of the immune micro‑environment, inhibition of angiogenesis, and direct anti‑myeloma activity through reduced proliferation and increased apoptosis of malignant cells.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Fatigue: mild to moderate tiredness.
• Diarrhea: loose stools, often transient.
• Rash: skin erythema or pruritus.
• Nausea: occasional upset stomach.
• Constipation: reduced bowel movements.
• Peripheral edema: mild swelling of extremities.

Serious or Rare Side Effects

• Thromboembolic events: deep‑vein thrombosis or pulmonary embolism.
• Severe neutropenia or leukopenia: markedly reduced white blood cell counts.
• Secondary primary malignancies: rare occurrence of new cancers.
• Hepatotoxicity: elevated liver enzymes or liver injury.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor for known adverse events.

• Pregnancy: contraindicated (Category X); teratogenic risk requires effective contraception.
• Renal impairment: dose adjustment may be needed based on creatinine clearance.
• Thrombotic risk: consider prophylactic anticoagulation in high‑risk patients.
• Hematologic monitoring: regular CBCs to detect neutropenia or anemia.
• Drug interactions: review concomitant medications for CYP3A4 inducers or inhibitors.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lenalidomide can interact with several drug classes, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may markedly reduce lenalidomide exposure.
• Anticoagulants (e.g., warfarin, DOACs): increased risk of bleeding.
• Live vaccines: reduced efficacy and potential infection risk.

Moderate Interactions (Monitor Closely)

• P‑glycoprotein inhibitors (e.g., cyclosporine): may raise plasma concentrations.
• Immunosuppressants (e.g., corticosteroids): additive immunomodulatory effects.
• NSAIDs: may exacerbate renal toxicity when combined with lenalidomide.